TNYA TENAYA THERAPEUTICS INC

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced management’s participation in two upcoming investor conferences.

Details of each presentation are as follows:

Morgan Stanley 20th Annual Global Healthcare Conference

Fireside chat

Date: September 13, 2022

Time: 3:30 p.m. ET / 12:30 p.m. PT

H.C. Wainwright 24th Annual Global Investment Conference

Company presentation

Date: September 14, 2022

Time: 3:00 p.m. ET / 12:00 p.m. PT

Webcasts of these events will be available by visiting the Investors section of . A replay of each webcast will be available on the Tenaya website for approximately 30 days following each conference.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit .

Investors

Michelle Corral

Tenaya Therapeutics

Media

Wendy Ryan

Ten Bridge Communications



EN
06/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TENAYA THERAPEUTICS INC

 PRESS RELEASE

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses.  Tenaya intends to use the net proceeds from the offerin...

 PRESS RELEASE

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares o...

 PRESS RELEASE

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical...

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Admin...

 PRESS RELEASE

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RID...

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 20...

 PRESS RELEASE

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and P...

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch